Lecanemab use in Chinese patients with Alzheimer's disease: a 12‐month multicenter real‐world study
Hao Wu, Qin Chen, Min Fang, Huidong Tang, Huayan Liu, Jun Liu, Jiewen Zhang, Lijun Chi, Shuai Liu, Jiawei Xin, Lumin Leng, Pan Wang, Song Chi, Yi Li, Jianwen Chen, Ligong Zhang, Jinhong Zhang, Qiang Ma, Xuezhen Wang, Xinling Meng, Jianfei Nao, Xiangqing Li, Yan Lv, Yanhong Jia, Qing Zhao, Chunyan Liu, Jinghuan Gan, Jing Zhu, Yehua Song, Huaian Li, Min Fei, Xia Guo, Jingwen Liu, Guoping Peng, Xiaochun Chen, Yong JiAbstract
INTRODUCTION
We evaluated lecanemab's safety and cognitive outcomes in Chinese patients with Alzheimer's disease (AD) and the utility of blood‐based biomarkers (BBMs) for treatment guidance.
METHODS
A multicenter, real‐world cohort enrolled 1042 patients receiving lecanemab, with 453, 359, 97 patients followed up at 3, 6, 12 months, respectively. Safety outcomes included amyloid‐related imaging abnormalities (ARIA) and infusion‐related reactions (IRRs), and the main clinical outcome was Clinical Dementia Rating Scale–Sum of Boxes (CDR‐SB) score change.
RESULTS
Of 1,042 patients, ARIA occurred in 7.87%, and IRRs in 16.12%. Discontinuation was 16.51%, mainly due to financial burden. CDR‐SB did not change at 12 months overall or in any subgroup. High‐accuracy BBMs were the sole AD biomarker assay in 5.28%, with comparable outcomes.
DISCUSSION
Lecanemab exhibited favorable 12‐month safety, with no clear evidence of cognitive decline, and BBMs hold potential for treatment guidance. Further studies using a control group are now warranted.